IL2 and cancer: However, administration of IL-2 adversely impacted host survival in the hu-PBMC-MHC I/II mice due to increased induction of graft versus host disease [22], which would pose a potential issue in the use of our TPV/Δ66R/mIL-2 recombinant during cancer studies.